With some unexpected industries tumbling and surging and considering the recent market fluctuations, more and more investors are seeking investment in small cap stocks in an attempt to enrich their portfolios.

At times it appears tough to navigate the field of small cap firms in order to know where true potential lies. However, one standout firm making some intriguing moves recently is Anavex Life Sciences Corp (OTCMKTS:AVXL), a company focused on drug advancement for various cancers, central nervous system diseases and Alzheimer’s. The company’s flagship drug is ANAVEX 2-73, which is in Phase 2a trials.

The update

Anavex Life stated that enrollment of patients for its planned Phase IIa Anavex2-73 clinical study has been completed ahead of schedule. It comes as a big achievement for the company as now it will be able to report top line results of Part-A study before this year’s end. The CEO Christopher U. Missling, PhD, expressed that there has been noteworthy interest in planned Phase 2a Alzheimer’s study, which is clearly seen in the full enrollment of the study.

Anavex team is thrilled to be ahead of schedule and value the support of enrolled patients and their families. They look forward to the results of ANAVEX 2-73 Phase IIa trial report and they are delighted to advance the clinical program.

The highlights

“ANAVEX 2-73” is the flagship oral medication in its Phase IIa trial targeting Alzheimer’s disease. It targets muscarinic and sigma-1 receptors, which is considered using upstream means to lower beta amyloid, tau and inflammation and protein misfolding. The market of Alzheimer’s drug is huge as over 25 million people are diagnosed with the disease and by 2050 this number is expected to reach 100 million.

In last trading session, the stock price of Anavex extended its gains and closed in green at $1.42.


It was another quiet day for Anavex Life Sciences Corp (OTCMKTS:AVXL) as it ended the last trading session with a minor gain of 0.71%. The volume of the day at 1.7 million against the daily average of 1.9 million reflected the indifference of the investors. The stock has found renewed interest from the long term investors this year, as indicated by the surging volume in the last few months accompanied by a huge appreciation of price. For the last few weeks, the stock has been consolidating in the range of $1.00-$1.70, a much needed pause before it can rally further.